News Article | May 8, 2017
-- Global brain monitoring market is expected to reach USD 2.0 billion by 2024 from USD 1.2 billion in 2016, at a CAGR of 7.1% in the forecast period 2017 to 2024.The global radiotherapy market is segmented based on therapy, product, application and geography.· EEG· TCD· MEG· MRI· CT· PET· EMG· Internal beam radiotherapy· Systemic radiation therapy· Traumatic Brain Injury (TBI)· Headache, dementia· Epilepsy· ParkinsonBased on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world.· Nihon Kohden Corporation· Philips Healthcare, Metronic PLC· GE Healthcare, Siemens Healthcare· Natus Medical Incorporated, Compumedics Limited· Electrical Geodesics, Inc. CAS Medical Systems Inc· Advanced Brain Monitoring· B. Braun Medical, Becton· Dickinson & Company· DePuySynthes Companies· Cadwell Industries, Inc· Masimo Corporation· Elekta AB (pub)· Integra LifeSciences Corporation· Rimed Inc.· Yokogawa Electric Corporation· EMOTIV Inc.and Neural AnalyticsReport Access: http://databridgemarketresearch.com/ reports/global- radiot... Data Bridge Market Research4th Floor, Mega Center,Magarpatta City, Pune – 411028Tel: +1-888-387-2818Email: Sales@databridgemarketresearch.comVisit Data Bridge Blog@ http://databridgemarketresearch.com/blog/LinkedIn: https://www.linkedin.com/company/data-bridge-market-research
News Article | April 18, 2017
The brain monitoring devices global market is expected to grow at mid single digit CAGR to reach $10,011.5 million by 2023. Brain monitoring devices market is mainly classified into products, application and end-users. The product classification consists of electroencephalography (EEG) devices, magnetoencephalography (MEG) devices, transcranial Doppler sonography (TCD) devices, intracranial pressure (ICP) monitors, cerebral oximeters, magnetic resonance imaging (MRI) devices, computerized tomography (CT) devices, positron emission tomography (PET) devices, sleep monitoring devices and accessories. The electroencephalography devices market is further segmented into by product type which includes 8-channel, 21-channel, 25-channel, 32-channel, 40-channel and multi-channel and by modality includes standalone/fixed EEG devices and portable EEG devices. The magnetic resonance imaging is divided based upon technology into low and middle field MRI, high field MRI and very high field MRI. Finally computed tomography devices is further classified into low slice CT, medium slice CT and high slice CT depending on the technology. The global brain monitoring devices market by application is segmented into neurodegenerative disorders, brain tumor, sleep disorders, psychiatric behavioural disorders and other applications. The neurodegenerative disorders is sub segmented into epilepsy, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury (TBI) and dementia whereas sleep disorders is sub classified into sleep apnea, insomnia, hypersomnia and sleep movement disorders. Psychiatric behavioural disorders are sub divided into autism, schizophrenia, dyslexia, bipolar disorders and depression. Other application is sub segmented into surgery, headache disorders, anesthesia and hydrocephalus. The end-users of brain monitoring devices market are hospitals, home care, ambulatory surgical centers and clinics, diagnostic centers and other end users. While increasing focus on minimally invasive brain monitoring procedure and extended application of devices in clinical trials are some of the opportunities that are propelling the growth of the market. However shortage of trained professionals, high cost of complex devices, unfavourable reimbursement policies, stringent regulatory guidelines and competition from local players in emerging markets are hampering the growth of the market. Factors Influencing Market Drivers and Opportunities For more information about this report visit http://www.researchandmarkets.com/research/4bszvd/brain_monitoring Research and Markets Laura Wood, Senior Manager email@example.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-brain-monitoring-devices-market-2017-2023-increasing-focus-on-minimally-invasive-brain-activity-monitoring-procedures---research-and-markets-300441027.html
News Article | April 25, 2017
Receive press releases from IQ4I Research & Consultancy Pvt. Ltd.: By Email IQ4I Research & Consultancy Published a New Report on "Brain Monitoring Devices Global Market Forecast to 2023" Brain monitoring devices aid in understand the activity of brain and explore structure and functions. Increasing incidence and prevalence neurological diseases, rising awareness, technological advancements/innovations are driving the market growth. Boston, MA, April 25, 2017 --( Brain monitoring devices market is growing at a steady rate, as estimated by IQ4I Research the market is expected to reach $10.01billion by 2023. The major factors driving the brain monitoring device market includes growing incidence and prevalence of neurological disorders, rising awareness about neurodegenerative disorders, growing healthcare spending and technological advancements/innovations offering wider scope of applications for brain monitoring. However, some of the factors like shortage of trained professionals, high cost of complex devices, stringent regulations and unfavorable reimbursement policies may hinder the growth of global brain monitoring device market. The brain monitoring devices global market is segmented based on their products, applications, end users and geography. Among products, sleep monitoring devices holds the largest market share because of the advancements in portable sleep devices technologies and growing incidence of obstructive sleep apnea. Sleep monitoring devices is expected to grow at the single digit mid-CAGR. The global brain monitoring devices application segment is classified into neurodegenerative disorders, brain tumor, psychiatric disorders, sleep disorders and other applications. Neurodegenerative diseases are characterized by progressive loss of neurons in the central nervous system and Epilepsy, Parkinson's disease (PD), Huntington’s disease falls under this category. In 2016, the market was estimated to be dominated by neurodegenerative disorders. The large share of this segment can be attributed to the growing incidence of Traumatic Brain Injuries (TBIs) globally owing to various factors like, increasing occurrence of falls, blunt trauma and motor vehicle crashes among other causes of TBIs and along with the increasing aging population. Geographically, the bran monitoring devices market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America region held the largest market share within that United States accounted for the largest share this growth is driven due to its high acceptance of advanced technologies and sophisticated universal treatment facilities. Asia- Pacific region is the fastest growing region due to its increase in healthcare spending and advancements in healthcare facilities, the easy access to advanced healthcare technology. The global brain monitoring devices market is fragmented where key players like GE Healthcare (U.S.), Philips N.V. (Netherland), Siemens Healthineers (Germany), Medtronic (Ireland) and Natus Medical Inc. (U.S.) holding a major share in 2016. The protection of intellectual property rights plays a very important role as a long term strategy for survival of the company and to maintain a competitive advantage. According to IQ4I Analysis, Advanced Brain Monitoring filed the largest number of PCT applications followed by Siemens Healthineers and Philips N.V. at World Intellectual Property Organization (WIPO). Some of the prominent players in brain monitoring device market include Advanced Brain Monitoring (U.S.), Cadwell Laboratories (U.S.), CAS Medicals Inc. (U.S), Compumedics Limited (Australia), Electrical Geodesics Incorporated (U.S.), Elekta AB (Sweden), GE Healthcare (U.S.), Integra Lifesciences (U.S.), Koninklijke Philips N.V. (Netherland), Masimo corporation (U.S.), Medtronic (Ireland), Natus Medical Inc.(U.S.), Nihon Kohden Corporation (Japan) and Siemens Healthineers (Germany). Boston, MA, April 25, 2017 --( PR.com )-- Brain monitoring devices are used to monitor and diagnose the neurological conditions by exploring the structure and functions of the brain in patients. These devices provide the information of the brain and greater understanding of neurological problems, with possible new treatments. Among brain monitoring devices CT and MRI are the conventional devices which are being used for the structural diagnosis of the brain like tumour, head injury etc., whereas EEG, MEG, TCD, oximeters and ICP monitors are the recent techniques used for the functional imaging of the brain. EEG measures the electrical activity generated by the various cortical layers of the brain whereas, MEG capture the magnetic fields generated by neural activity within the brain. Similarly, TCD measures the velocity of the blood flow through the brain’s blood vessels, oximeters are used to measure the regional cerebral oxygen saturation with in the brain and ICP monitors monitor the intracranial pressure within the skull while treating severe traumatic brain injury in patients. In addition to all these devices, sleep monitoring devices which occupies major share in the brain monitoring devices global market, are being used to understand the person’s sleep physiology and track sleep with the aim of finding patterns and correlations with person’s behaviours.Brain monitoring devices market is growing at a steady rate, as estimated by IQ4I Research the market is expected to reach $10.01billion by 2023. The major factors driving the brain monitoring device market includes growing incidence and prevalence of neurological disorders, rising awareness about neurodegenerative disorders, growing healthcare spending and technological advancements/innovations offering wider scope of applications for brain monitoring. However, some of the factors like shortage of trained professionals, high cost of complex devices, stringent regulations and unfavorable reimbursement policies may hinder the growth of global brain monitoring device market.The brain monitoring devices global market is segmented based on their products, applications, end users and geography. Among products, sleep monitoring devices holds the largest market share because of the advancements in portable sleep devices technologies and growing incidence of obstructive sleep apnea. Sleep monitoring devices is expected to grow at the single digit mid-CAGR.The global brain monitoring devices application segment is classified into neurodegenerative disorders, brain tumor, psychiatric disorders, sleep disorders and other applications. Neurodegenerative diseases are characterized by progressive loss of neurons in the central nervous system and Epilepsy, Parkinson's disease (PD), Huntington’s disease falls under this category. In 2016, the market was estimated to be dominated by neurodegenerative disorders. The large share of this segment can be attributed to the growing incidence of Traumatic Brain Injuries (TBIs) globally owing to various factors like, increasing occurrence of falls, blunt trauma and motor vehicle crashes among other causes of TBIs and along with the increasing aging population.Geographically, the bran monitoring devices market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America region held the largest market share within that United States accounted for the largest share this growth is driven due to its high acceptance of advanced technologies and sophisticated universal treatment facilities. Asia- Pacific region is the fastest growing region due to its increase in healthcare spending and advancements in healthcare facilities, the easy access to advanced healthcare technology.The global brain monitoring devices market is fragmented where key players like GE Healthcare (U.S.), Philips N.V. (Netherland), Siemens Healthineers (Germany), Medtronic (Ireland) and Natus Medical Inc. (U.S.) holding a major share in 2016. The protection of intellectual property rights plays a very important role as a long term strategy for survival of the company and to maintain a competitive advantage. According to IQ4I Analysis, Advanced Brain Monitoring filed the largest number of PCT applications followed by Siemens Healthineers and Philips N.V. at World Intellectual Property Organization (WIPO).Some of the prominent players in brain monitoring device market include Advanced Brain Monitoring (U.S.), Cadwell Laboratories (U.S.), CAS Medicals Inc. (U.S), Compumedics Limited (Australia), Electrical Geodesics Incorporated (U.S.), Elekta AB (Sweden), GE Healthcare (U.S.), Integra Lifesciences (U.S.), Koninklijke Philips N.V. (Netherland), Masimo corporation (U.S.), Medtronic (Ireland), Natus Medical Inc.(U.S.), Nihon Kohden Corporation (Japan) and Siemens Healthineers (Germany). Click here to view the list of recent Press Releases from IQ4I Research & Consultancy Pvt. Ltd.
News Article | November 23, 2016
« Bosch introduces Power Max 2 and Power Max 2Plus chargers in N America; output up to 40 Amps, smaller footprint, WiFi | Main | Juniper Research: taxi sector to lead self-driving market to >22M consumer vehicles on the road by 2025 » At Bauma China 2016, Asia’s biggest trade fair for construction equipment, DEUTZ and its Chinese joint venture, DEUTZ (Dalian) Engine (DDE) unveiled new TCD 9.0 four-cylinder diesel engine. The 9.0-liter unit is the first in a new generation of engines that DEUTZ is planning as part of an alliance with the Liebherr Group. As well as the TCD 9.0, this comprises six-cylinder diesel engines. The engines made by Liebherr within this cooperation will be sold by DEUTZ under its own brand. The plan is for DEUTZ’s Chinese joint venture to manufacture the TCD 9.0 under licence so that it can more easily serve the local market. The engine has a power rating of 300 kW (402 hp) and produces 1,700 N·m (1,254 lb-ft) of torque. It also features a highly compact design that makes it easy to install in a wide range of applications and is particularly well suited for excavators and wheel loaders. All new engines are being developed for the EU Stage V, US Tier 4, China IV and EU Stage IIIA emissions standards and will be ready to go into series production in 2019. They will follow a standardized concept with a common customer interface and a high proportion of shared parts and are to be distributed via DEUTZ’s global network of dealers and service outlets. DEUTZ is leading the way in exhaust aftertreatment using highly developed systems such as the diesel particulate filter (DPF), selective catalytic reduction (SCR) and diesel oxidising catalyst (DOC). The familiar DEUTZ engine portfolio (TCD 2.2 to TCD 16.0) and the new Liebherr engines all meet the EU’s most stringent emissions standard, Stage V (applies from 2019). Emission downgrade versions will also be available, meaning a single engine platform can be used both for Stage V markets and for regions with more relaxed regulations. In addition to the TCD 9.0, DEUTZ is exhibiting the successful TCD 2.9 in Shanghai as an example of its compact engines. This small four-cylinder engine is now also available as a High Power (HP) version with a power rating of 75 kW (101 hp) and as a High Torque (HT) version with 375 N·m (277 lb-ft) of torque. The High Torque variant still falls below the relevant power output threshold of 56 kW (75 hp) and consequently does not need an SCR system to comply with EU Stage V. Because of these engines’ increased power rating and torque, they can be used in place of much bigger engines, leading to savings in weight, installation space and costs. From 2019, the TCD 2.9 will also be manufactured in China by DEUTZ’s Chinese joint venture DEUTZ (Dalian) Engine.
News Article | November 14, 2016
L'i-plaqtest destiné au dosage de la Lp-PLA est un test sanguin simple qui contribue en mesurant le taux de phospholipase A associée aux lipoprotéines à évaluer le risque de maladie coronarienne et d'accidents vasculaires cérébraux ischémiques associés à l'athérosclérose L'i-plaq test permet à Technopath Clinical Diagnostics d'accéder à un nouveau et vaste segment de marché en pleine expansion Technopath Clinical Diagnostics (« Technopath ») a annoncé aujourd'hui le lancement de son premier kit de réactifs de diagnostic bénéficiant du marquage CE, l'i-plaq test. TCD est une société axée sur l'innovation non cotée en bourse spécialisée dans le diagnostic in vitro et le numéro un mondial des supports de contrôle de la qualité par des tiers consolidés par des tests grâce à ses solutions logicielles d'évaluation par des pairs en temps réel. L'i-plaq test pour le dosage de la Lp-PLA permet aux cliniciens de déceler rapidement au moyen d'une analyse de sang standard la Lp-PLA , un marqueur spécifique de l'inflammation vasculaire qui joue un rôle crucial dans la formation de plaques sujettes à rupture. Des niveaux élevés de Lp-PLA peuvent être le signe d'un risque accru de rupture de la plaque athéroscléreuse laquelle peut provoquer l'apparition d'un caillot de sang dangereux susceptible de déclencher des accidents cardiovasculaires (MCV). TCD estime que les performances supérieures et la facilité d'utilisation du test i-plaq permettront d'améliorer sensiblement l'évaluation du risque de MCV chez les patients. « Nous sommes ravis d'annoncer la commercialisation du kit i-plaqtest, un test à la fois facile à utiliser, fiable et qui permet d'obtenir des résultats de grande qualité dans des proportions significatives d'un point de vue clinique », a déclaré Malcolm Bell, PDG de Technopath Clinical Diagnostics. « Ce lancement constitue une opportunité de développement non négligeable pour notre société qui vise des produits complémentaires sur ce nouveau et vaste segment de marché en plein essor. » Les performances analytiques et cliniques de l'i-plaq test pour le dosage de la Lp-PLA ont été confirmées par des essais complets réalisés conformément aux directives réglementaires auprès d'un grand nombre d'échantillons sur des sites internationaux. La Lp-PLA a pour sa part fait l'objet d'essais cliniques de grande envergure dont les résultats sont parus dans plus de 1 000 publications, pour ne citer que les méta-analyses de 79 036 participants à 32 études prospectives publiées dans la revue Lancet(1). Ces publications ont montré que la concentration en Lp-PLA est un prédicteur de risque de maladie coronarienne (MC) avec un rapport de risque similaire à celui de la tension artérielle systolique et du cholestérol non-HDL. Dans la sous-étude LIPID(2), il a été démontré qu'une baisse de l'activité de la Lp-PLA est un très important prédicteur de réduction du risque de survenue d'évènements coronariens ultérieurs. Les évènements liés aux maladies cardiovasculaires (MCV) sont la première cause de mortalité en Europe et aux États-Unis avec près de 800 000 décès en 2015 aux États-Unis auxquels s'ajoutent 795 000 victimes d'accidents vasculaires cérébraux, principale cause d'invalidité évitable. Environ 50 % des évènements liés aux MCV surviennent chez des patients présentant des taux de lipides banals. Le nombre de personnes développant un syndrome métabolique a par ailleurs augmenté pour atteindre près de 50 % des patients de plus de 50 ans. Dans l'idéal, l'ensemble des facteurs de risque de coronaropathie devraient être bien maîtrisés. Des preuves de plus en plus nombreuses témoignent de l'impact positif accru de toute modification sensible d'un facteur de risque individuel. Selon l'American Heart Association, la MCV est la première cause de mortalité aux États-Unis mais aussi dans le monde. Elle est en effet à l'origine de 31 % des décès, toutes causes confondues, contre 12 % pour les AVC. Il est impératif de garder une bonne santé cardiovasculaire en modifiant son mode de vie ainsi qu'en connaissant et traitant les facteurs de risque. Technopath Clinical Diagnostics est une société irlandaise en plein essor du secteur des sciences du vivant. Tournée vers l'innovation et non cotée en bourse, elle a été fondée en 2004. La société compte parmi les leaders mondiaux du développement et de la fabrication de solutions de contrôle de la qualité et de logiciels qui améliorent la qualité des tests réalisés sur les patients ainsi que le rendement des laboratoires cliniques. Technopath Clinical Diagnostics opère sur le marché du diagnostic in vitro (« DIV »), l'un des segments du marché des sciences du vivant qui connaît la plus forte croissance. La société, qui a lancé ses premiers produits en 2008, est aujourd'hui commercialement présente dans plus de 100 pays dans le monde. En 2012, elle a signé un accord d'approvisionnement avec Abbott et a vu la commercialisation de son premier produit autorisée aux États-Unis par la FDA en 2013. Pour plus d'informations, veuillez consulter le site http://www.technopathclinicaldiagnostics.com
News Article | November 23, 2016
« DEUTZ unveils new TCD 9.0 4-cylinder diesel in Shanghai | Main | DOE awards $1.1M to Penn State project to develop protective, self-healing layers for Li metal anodes » New findings from Juniper Research project that the annual production of self-driving cars will reach 14.5 million in 2025, up significantly from only a few thousands in 2020, resulting in a global installed base of more than 22 million consumer vehicles by 2025. The new research, Autonomous Vehicles & ADAS: Adoption, Regulation & Business Models 2016-2025, found that the market adoption of AV (Autonomous Vehicle) technology is set to accelerate over the next few years, driven by increasingly stringent vehicle safety specifications; environmental pressures; and rapid technological developments. The research suggests that driverless vehicles will have a disruptive impact on transportation around the world and will ultimately lead to millions of professional drivers being made redundant. Juniper predicts that city-based taxi services will be one of the key early adopters of driverless vehicles. However, the research cautioned that following the first fatality in an AV vehicle—the recent Tesla S accident in Florida—the AV industry must convince the public that their vehicles are completely safe. Juniper found that a number of major OEMs including BMW, Toyota and GM are accelerating their AV development and testing programmes and now have firm plans to launch production vehicles. As a result, Juniper forecasts that driverless vehicles will start to become widespread in the 2020-2025 timeframe, although they will initially be confined to city centers or key routes due to the need for extensive V2X (Vehicle-To-Everything) infrastructure. Juniper believes that Level 4 vehicles will not be deployed in any significant numbers until well into the second half of the forecast period (2020-2025), although some OEMs expect to launch some vehicles before 2020. Juniper expects that the Far East & China region will either lead, or at least be on a par, with North America and West Europe in terms of the number of Level 4 vehicles deployed at the end of 2020. Juniper expects the Far East & China region to extend its market position thereafter so that by the end of 2025, it will dominate the market with a market share of 34%, followed by North America and West Europe. Unsurprisingly, the lowest adoption rates will be seen in the less affluent regions of the Indian Subcontinent, Rest of Asia Pacific and Africa & Middle East. ABI Research: OEMs Target 2021 for rollout of Levels 4 and 5 of autonomous driving. A separate study by ABI Research projects that semi-autonomous systems will continue to dominate the market over the next decade, with SAE level 2 and 3 systems accounting for 86% of autonomous vehicles shipping in 2026. Higher levels of autonomy will gain traction quickly, representing just under one-third of autonomous vehicles shipping in 2030. Driverless cars will transform the way mobility is consumed, bringing environmental, societal and convenience advantages to the end user. It also represents a fundamental disruption to the business model that dominated the automotive market for almost one century. OEMs have much to gain in pursuing semi-autonomous operation, maintaining the importance of the driving experience. However, recent announcements from BMW, Ford, Renault-Nissan, and Tesla signal that OEMs are not only looking to introduce higher levels of autonomy by 2021, but are also actively planning to transition from vehicle sellers to mobility providers. Both Ford and Renault-Nissan launched smart mobility divisions to build on the existing trend of OEM/rideshare partnerships and investments. The divisions also provide a platform for these brands to research and implement autonomous and connected technologies. Meanwhile, the recently announced Tesla Network details how the brand intends to facilitate peer-to-peer autonomous car sharing, and how participation will impact consumer car ownership costs. ABI Research finds Tesla’s decision to withdraw the level 2 Autopilot system in favor of Enhanced Autopilot, and eventually deep learning-based autonomous functionality, consistent with SAE level 4, or even level 5, to be the most concrete example of the shift in industry attitudes toward low level semi-autonomous driving.
News Article | November 9, 2016
DEUTZ will suppy engines to Sany, a construction equipment manufacturer headquartered in China with American offices in Peachtree City, GA. Sany will install DEUTZ TCD 7.8 diesel engines in its new SW405 wheel loaders. “DEUTZ engines are in many of the road construction machines used in the Chinese market,” said Kevin Grover, large excavator and wheel loader NPI manager at Sany America. “We looked at a few different suppliers, but the DEUTZ engine had an ideal torque curve for a wheel loader application. Furthermore, we feel the DEUTZ engine’s quality and responsiveness will help our machines truly perform at an optimum level.” DEUTZ’s water-cooled, six-cylinder, in-line TCD 7.8 diesel engines feature an exhaust aftertreatment system with a diesel particulate filter (DPF) and selective catalytic reduction (SCR) system. These engines meet U.S. EPA Tier 4 and E.U. Stage IV emissions standards, and thanks to their DPF, also fulfill the E.U.’s upcoming Stage V standards which will go into effect in 2019. “With DEUTZ’s Stage-V-ready engines, our machines are all set for the next round of emissions legislation,” Grover said. “We won’t have to go through another extensive design cycle when the new emissions regulations do take effect.” The TCD 7.8 diesel engines produce 250 to 390 hp (160 to 290 kW) at 2,300 revolutions per minute. A modular system of optional add-on components makes these compact engines exceptionally versatile. The DVERT® (DEUTZ Variable Emission Reduction Technology) system is also modular, meeting the individual requirements of various markets with the standard DPF/SCR system. “We designed our TCD 7.8 diesel engines to offer our OEMs customers greater flexibility and lower installation costs,” said Robert Mann, DEUTZ Corporation president and CEO. “Because these engines are both compact and modular, OEMs who choose them for their machines can develop more versatile designs to answer a broader range of end user needs.” Sany’s SW405 wheel loaders are engineered for use at various types of construction sites. Their typical tasks include hauling pipes, materials handling and snow removal. “We are delighted to have secured Sany as a customer in the field of construction machinery,” said Michael Wellenzohn, member of DEUTZ AG’s board of management with responsibility for sales, service and marketing. “Together, we’re looking forward to a successful partnership.” For more information about Sany, visit http://www.sanyamerica.com To learn more about DEUTZ Corporation and its complete line of diesel and natural gas engines, visit http://www.deutzamericas.com.
News Article | May 18, 2016
A newly discovered light form could challenge what scientists know about properties of light and transform fiber optic technology. Irish physicists were able to establish a light form that does not behave according to the recognized laws of angular momentum. A light beam is measured by its angular momentum, which remains constant unless an external torque is applied. It was always believed that the angular momentum is an integer of Planck's constant. However, Trinity College Dublin (TCD) and CRANN Institute researchers were able to show that a new light form with an angular momentum half of Planck's constant exists. Paul Eastham, the study's lead researcher and an assistant professor at TCD, said their experiment proved that properties of light, previously thought to be fixed, can actually be altered. "A beam of light is characterized by its color or wavelength and a less familiar quantity known as angular momentum. Angular momentum measures how much something is rotating. For a beam of light, although travelling in a straight line, it can also be rotating around its own axis," explained Professor John Donegan from CRANN. "So when light from the mirror hits your eye in the morning, every photon twists your eye a little, one way or another." For their experiment, the researchers used crystals to create a beam of light that appears as a screw-like structure. The team initially hoped to identify how to change the behavior of light for use in optical communications. However, as they were analyzing the beam covered by the quantum mechanics theory, they realized that the angular momentum was not a whole number - a discovery that debunks established theories on angular momentum. To test whether their observation was accurate, the team created a tool that would measure the angular momentum flow in the light beam and identify the flow variations due to quantum effects. They found that small angular momentum alterations of every photon are possible. CRANN director and co-researcher Stefano Sanvito said finding a new light form is indeed a breakthrough in the world of physics and science. However, more studies should be done to back up the recent discovery. If a new light form truly exists, the fiber optic industry will greatly benefit by creating faster and more secure Internet connections. Just recently, Russian scientists were able to develop a long-distance quantum communication device that ensures the safe delivery of information. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.
News Article | December 8, 2016
Prof. Jonathan Coleman is with his graphene-putty alongside his son Oisin, trying out the novelty children's material silly putty. Credit: AMBER, Trinity College Dublin Researchers in AMBER, the Science Foundation Ireland-funded materials science research centre, hosted in Trinity College Dublin, have used the wonder material graphene to make the novelty children's material silly putty (polysilicone) conduct electricity, creating extremely sensitive sensors. This world first research, led by Professor Jonathan Coleman from TCD and in collaboration with Prof Robert Young of the University of Manchester, potentially offers exciting possibilities for applications in new, inexpensive devices and diagnostics in medicine and other sectors. The AMBER team's findings have been published this week in the leading journal Science. Prof Coleman, Investigator in AMBER and Trinity's School of Physics along with postdoctoral researcher Conor Boland, discovered that the electrical resistance of putty infused with graphene ("G-putty") was extremely sensitive to the slightest deformation or impact. They mounted the G-putty onto the chest and neck of human subjects and used it to measure breathing, pulse and even blood pressure. It showed unprecedented sensitivity as a sensor for strain and pressure, hundreds of times more sensitive than normal sensors. The G-putty also works as a very sensitive impact sensor, able to detect the footsteps of small spiders. It is believed that this material will find applications in a range of medical devices. Prof Coleman said, "What we are excited about is the unexpected behaviour we found when we added graphene to the polymer, a cross-linked polysilicone. This material as well known as the children's toy silly putty. It is different from familiar materials in that it flows like a viscous liquid when deformed slowly but bounces like an elastic solid when thrown against a surface. When we added the graphene to the silly putty, it caused it to conduct electricity, but in a very unusual way. The electrical resistance of the G-putty was very sensitive to deformation with the resistance increasing sharply on even the slightest strain or impact. Unusually, the resistance slowly returned close to its original value as the putty self-healed over time." He continued, "While a common application has been to add graphene to plastics in order to improve the electrical, mechanical, thermal or barrier properties, the resultant composites have generally performed as expected without any great surprises. The behaviour we found with G-putty has not been found in any other composite material. This unique discovery will open up major possibilities in sensor manufacturing worldwide." Professor Mick Morris, Director of AMBER, said: "This exciting discovery shows that Irish research is at the leading edge of materials science worldwide. Jonathan Coleman and his team in AMBER continue to carry out world class research and this scientific breakthrough could potentially revolutionise certain aspects of healthcare." Explore further: Flying start for world's first graphene-enhanced aircraft
News Article | November 14, 2016
The i-plaqtest for Lp-PLA is a simple blood test which measures Lipoprotein-Associated Phospholipase A as an aid to assessing risk of both coronary heart disease and ischemic stroke associated with atherosclerosis i-plaq test represents entry into a large and growing new market segment for Technopath Clinical Diagnostics Technopath Clinical Diagnostics ("Technopath") today announced the launch of its first CE marked diagnostic reagent kit, the i-plaq test. TCD is an innovation driven privately owned in vitro diagnostic company and the global leader in test-consolidated third party quality control materials with real time peer review software solutions. The i-plaq test for Lp-PLA enables clinicians to quickly detect Lp-PLA , a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque from a standard blood test. Higher levels of Lp-PLA may indicate that the atherosclerotic plaque is more likely to rupture, leading to a dangerous blood clot that could result in cardiovascular disease (CVD) events. TCD expects that i-plaq's superior test performance and ease of use will significantly improve the CVD risk assessment for patients. "We are very excited to announce the commercialization of the i-plaqtest kit, a test that is both easy to use and reliable while generating high quality patient results at clinically significant ranges," said Malcolm Bell, CEO of Technopath Clinical Diagnostics. "This launch represents a significant development opportunity for our company as we target additional products for this large and growing new market segment." The i-plaq test for Lp-PLA has been comprehensively tested at a number of international sites with a large number of samples in accordance with regulatory guidelines to confirm analytical and clinical performance. Lp-PLA has been tested in large clinical trials and results have been published in more than 1,000 publications like the meta- analyses of 79,036 participants in 32 prospective studies published in the Lancet(1). This publication demonstrated that Lp-PLA was a predictor of coronary heart disease (CHD), with a risk ratio similar in magnitude to that of systolic blood pressure and non-HDL cholesterol. In the LIPID(2) sub-study it was shown that the reduction of Lp-PLA activity was a highly significant predictor of reduction in subsequent coronary events. CVD events are the leading cause of deaths in Europe and the US. CVD caused nearly 800,000 deaths in 2015 in the US and about 795,000 people had a stroke, the leading preventable cause of disability. Around 50% of CVD events occur in patients with unremarkable lipid levels. Further the number of people developing metabolic syndrome has gone up to almost 50% of patients >50 years of age. Ideally, all coronary artery disease (CAD) risk factors should be well controlled, and increasing evidence shows an enhanced benefit when each individual risk factor is aggressively modified. According to the American Heart Association CVD is not only the top killer in the US but worldwide with 31 percent of all deaths from CVD, and stroke accounted for nearly twelve percent of all deaths. There is a need to maintain good cardiovascular health through lifestyle changes and recognition and treatment of risk factors. Technopath Clinical Diagnostics is an innovation driven high growth privately held Irish life sciences company founded in 2004. We are a global leader in the development and manufacture of quality controls and software which enhance the quality of patient testing and the efficiency of clinical laboratories. Technopath Clinical Diagnostics operates in the In Vitro Diagnostics ("IVD") market - one of the fastest growing life science market segments. We launched our first products in 2008 and these are now sold globally in over 100 countries. In 2012, we signed a global supply agreement with Abbott and in 2013 achieved our first US product approval from the FDA. For more information please go to http://www.technopathclinicaldiagnostics.com